Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID-19 pandemic: A population-based, nation-wide study
Research output: Contribution to journal › Letter › Research › peer-review
Documents
- Fulltext
Final published version, 0.99 MB, PDF document
Patients with B-cell-derived malignancies are at increased risk of severe coronavirus disease 2019 (COVID-19) due to the inherent immune dysfunction and/or treatment. To protect patients in general and patients with B-cell-derived malignancies in particular from COVID-19, management of these patients was changed toward virtual consultations during the pandemic. Whether the COVID-19 pandemic itself and/or changes in management have led to excess mortality among hematological patients during the COVID-19 pandemic in Denmark has not yet been investigated.
Original language | English |
---|---|
Article number | e57 |
Journal | HemaSphere |
Volume | 8 |
Issue number | 3 |
Number of pages | 3 |
ISSN | 2572-9241 |
DOIs | |
Publication status | Published - 2024 |
ID: 385889080